AU2020270917B2 - Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione - Google Patents

Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Info

Publication number
AU2020270917B2
AU2020270917B2 AU2020270917A AU2020270917A AU2020270917B2 AU 2020270917 B2 AU2020270917 B2 AU 2020270917B2 AU 2020270917 A AU2020270917 A AU 2020270917A AU 2020270917 A AU2020270917 A AU 2020270917A AU 2020270917 B2 AU2020270917 B2 AU 2020270917B2
Authority
AU
Australia
Prior art keywords
compound
subject
rituximab
dlbcl
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020270917A
Other languages
English (en)
Other versions
AU2020270917A1 (en
Inventor
Maria Soraya Carrancio ANTON
Tonia J. Buchholz
Antonia Lopez-Girona
Rama Krishna Narla
Michael POURDEHNAD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2020270917A1 publication Critical patent/AU2020270917A1/en
Application granted granted Critical
Publication of AU2020270917B2 publication Critical patent/AU2020270917B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020270917A 2019-04-12 2020-04-09 Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione Active AU2020270917B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833432P 2019-04-12 2019-04-12
US62/833,432 2019-04-12
PCT/US2020/027358 WO2020210418A1 (en) 2019-04-12 2020-04-09 Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Publications (2)

Publication Number Publication Date
AU2020270917A1 AU2020270917A1 (en) 2021-11-04
AU2020270917B2 true AU2020270917B2 (en) 2025-08-28

Family

ID=70465546

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020270917A Active AU2020270917B2 (en) 2019-04-12 2020-04-09 Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Country Status (26)

Country Link
US (3) US11390617B2 (https=)
EP (1) EP3952880B1 (https=)
JP (1) JP7562557B2 (https=)
KR (1) KR102944213B1 (https=)
CN (1) CN114144182B (https=)
AR (1) AR119715A1 (https=)
AU (1) AU2020270917B2 (https=)
BR (1) BR112021020372A2 (https=)
CA (1) CA3132538A1 (https=)
CL (1) CL2021002651A1 (https=)
DK (1) DK3952880T3 (https=)
ES (1) ES3061998T3 (https=)
FI (1) FI3952880T3 (https=)
HR (1) HRP20251668T1 (https=)
IL (1) IL287145A (https=)
LT (1) LT3952880T (https=)
MA (1) MA55608A (https=)
MX (1) MX2021012507A (https=)
PT (1) PT3952880T (https=)
RS (1) RS67593B1 (https=)
SG (1) SG11202111232RA (https=)
SI (1) SI3952880T1 (https=)
SM (1) SMT202600013T1 (https=)
TW (1) TWI853014B (https=)
WO (1) WO2020210418A1 (https=)
ZA (1) ZA202107668B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
AU2020369497B2 (en) 2019-10-21 2026-02-05 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
US11666579B2 (en) * 2019-10-21 2023-06-06 Celgene Corporation Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CA3154890A1 (en) * 2019-10-21 2021-04-29 Maria Soraya Carrancio ANTON Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion
JP7676375B2 (ja) 2019-10-21 2025-05-14 セルジーン コーポレーション （ｓ）－２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンおよびその塩を含む固形体、並びにそれを含む組成物およびそれを使用する方法
WO2021080955A1 (en) 2019-10-21 2021-04-29 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
CA3154908A1 (en) 2019-10-21 2021-04-29 Sreenivas S. Bhat Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the sam
AU2022252220A1 (en) * 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
JP2024515108A (ja) * 2021-04-21 2024-04-04 セルジーン コーポレーション ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用して非ホジキンリンパ腫を治療する方法
EP4326266A1 (en) * 2021-04-21 2024-02-28 Celgene Corporation Methods of treating b-cell lymphoma using combination therapy
WO2022271557A1 (en) 2021-06-21 2022-12-29 Celgene Corporation Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209692A1 (en) * 2018-04-23 2019-10-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002253795B2 (en) 2000-11-30 2007-02-01 The Children's Medical Center Corporation Synthesis of 4-Amino-Thalidomide enantiomers
PL2076260T3 (pl) * 2006-09-15 2011-08-31 Celgene Corp Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania
AU2010249615B2 (en) 2009-05-19 2013-07-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
EP2536706B1 (en) * 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
BR112015002285B1 (pt) * 2012-08-09 2022-05-10 Celgene Corporation Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer
HK1214552A1 (zh) 2012-11-05 2016-07-29 细胞基因公司 在腎損傷的受試者中用泊馬度胺治療癌症
CN105246480A (zh) * 2013-04-02 2016-01-13 细胞基因公司 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物
CN111205268B (zh) * 2014-10-30 2021-01-26 康朴生物医药技术（上海）有限公司 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用
TWI791552B (zh) * 2017-07-10 2023-02-11 美商西建公司 抗增生化合物及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209692A1 (en) * 2018-04-23 2019-10-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma

Also Published As

Publication number Publication date
HRP20251668T1 (hr) 2026-02-27
US20240400548A1 (en) 2024-12-05
KR20210151895A (ko) 2021-12-14
CN114144182A (zh) 2022-03-04
CN114144182B (zh) 2024-05-24
FI3952880T3 (fi) 2026-02-05
LT3952880T (lt) 2026-01-26
US20220324855A1 (en) 2022-10-13
RS67593B1 (sr) 2026-01-30
CL2021002651A1 (es) 2022-04-29
BR112021020372A2 (pt) 2021-12-07
JP2022527398A (ja) 2022-06-01
KR102944213B1 (ko) 2026-03-26
US20200325129A1 (en) 2020-10-15
SI3952880T1 (sl) 2026-02-27
EP3952880B1 (en) 2025-12-10
MX2021012507A (es) 2022-01-24
US11390617B2 (en) 2022-07-19
CA3132538A1 (en) 2020-10-15
TWI853014B (zh) 2024-08-21
EP3952880A1 (en) 2022-02-16
JP7562557B2 (ja) 2024-10-07
WO2020210418A1 (en) 2020-10-15
SMT202600013T1 (it) 2026-03-09
AR119715A1 (es) 2022-01-05
DK3952880T3 (da) 2026-01-26
ES3061998T3 (en) 2026-04-08
ZA202107668B (en) 2025-01-29
TW202103705A (zh) 2021-02-01
IL287145A (en) 2021-12-01
PT3952880T (pt) 2026-02-17
US12103923B2 (en) 2024-10-01
SG11202111232RA (en) 2021-11-29
MA55608A (fr) 2022-02-16
AU2020270917A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
AU2020270917B2 (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
EP4048279B1 (en) 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione for use in treating chronic lymphocytic leukemia
CN107073122A (zh) 恶性肿瘤的联合治疗
WO2021080935A1 (en) Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione
EA047955B1 (ru) Способы лечения неходжкинской лимфомы с использованием 2-(2,6-диоксопиперидин-3-ил)-4-((2-фтор-4-((3-морфолиноазетидин-1-ил)метил)бензил)амино)изоиндолин-1,3-диона
US20250017941A1 (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
US20240207281A1 (en) Methods of treating b-cell lymphoma using combination therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)